Monday, November 12, 2018

The Herpes Virus 'Potentially Heal' Skin Cancer

The Herpes Virus 'Potentially Heal' Skin Cancer

A version of the genetic engineering of a virus that usually causes herpes simplex disease or ' cold sores ' shows the potential for the treatment of skin cancer, the researchers said.

Modified herpes virus that is harmless to normal cells but when injected into tumors, a virus has doubled and the release of substances to fight cancer.

Trial results published in the Journal of Clinical Oncology shows this therapy can prolong life for several years — but only for some patients melanoma. This method of treatment has not been licensed.

Treatment is similar to that of immunotherapy is already available in the United States and Europe, but researchers believe the T-Vec will be a new addition that was greeted with good reviews. This will also be the first melanoma treatment using viruses.

This latest study is the largest randomized trial using the anticancer and viruses involving 436 patients from centers in 64 United States, United Kingdom, Canada and South Africa that have a melanoma malignant cannot be operated on.

The increase in survival
The leader of this research in the United Kingdom, Prof. Kevin Harrington, from the Institute of Cancer Research in London, said, "there's an increasing fervor for the use of the viral treatments such as the T-Vec for cancer, because they could launch attacks forked on the tumor-both kill cancer cells directly and commanding the immune system's resistance to cancer.

"And because the treatment of the virus can target cancer cells specifically, it tends to have fewer side effects than traditional chemotherapy or some other new immunotherapy.”

Dr. Hayley Frend, science information manager at Cancer Research UK, said, "previous research showed the T-Vec can work well for those with advanced skin cancer, but this is the first study that shows an increase in survival.

"The next step is to understand why only some patients are responding well to the treatment of the T-Vec, so that we know which patients can take benefit of this treatment."

Earlier this year, an immunotherapy drug, pembrolizumab, became the first treatment that "accelerated" in the United Kingdom the NHS for patients who suffered from melanoma, under new Government plans.

Drugs that are approved through the plan of Early Access to Medicines, which launched in the United Kingdom in April 2014, has been investigated by the watchdog which calculated the risks and the benefits that it causes.

Melanoma is a cancer that frequently occurs in United Kingdom and killed more than 2,000 per year there. Damage to the skin caused by the Sun's harmful UV rays increases the risk of incidence of this cancer.


Although not yet licensed, physicians are very excited by the prospect of this new melanoma treatment – and for the future, perhaps for other types of cancer.

The idea of using a virus to enter and kill the cancer cells are increasingly accepted science community and much praised.

A recent study in the Journal of Clinical Oncology is the largest randomized study for anticancer virus and provides promising evidence so that this concept can be applied in clinics, as well as a long-tested in the laboratory.

The researchers now want to do further studies to identify which patients can benefit from this treatment and whether it should be used along with other melanoma treatment.

The watchdog medicines will be watching closely and will make the final decision regarding the T-Vec in no time.

No comments:

Post a Comment